PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Negative net income growth while TRAW stands at 26.41%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
14.84%
Less D&A growth vs. TRAW's 33.33%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
0.81%
SBC growth while TRAW is negative at -18.75%. John Neff would see competitor possibly controlling share issuance more tightly.
106.29%
Slight usage while TRAW is negative at -157.89%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Some yoy usage while TRAW is negative at -383.92%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Operating cash flow growth above 1.5x TRAW's 1.17%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
38.16%
CapEx growth of 38.16% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
We expand invests by 38.16% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Issuance growth of 1171.17% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.